TMCnet News
GENFIT to Highlight Progress in ACLF and MASH Diagnostics at AASLD The Liver Meeting® 2026
Lille (France), Cambridge (Massachusetts, United States), November 2, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced a broad program of scientific and strategic activities taking place at the AASLD The Liver Meeting® 2026, highlighting progress across its therapeutic programs in Acute on-Chronic Liver Failure (ACLF) and diagnostics activities in Metabolic dysfunction-associated steatohepatitis (MASH). ACLF – Advancing a multi-target therapeutic strategy Scientific Event – November 8, 2026 |Advancing Clinical Development in ACLF Scientific posters to be presented – November 6, 2026 | 1:00–2:00 p.m. MT
ACLF is characterized by high systemic inflammation and profound immune dysregulation. By bridging systemic immune dysregulation and pharmacological intervention, posters #2284 and #2273 presented at The Liver Meeting® will provide new insights into the role of the immune system, particularly neutrophils, in acute liver failure conditions. In addition, poster #2034 will provide further evidence of nitazoxanide’s anti-inflammatory activity, using blood samples collected in a clinical setting, supporting its clinical development in ACLF. NACSELD Meeting – November 5, 2026 MASH Diagnostics – Unlocking the opportunity as MASH treatment uptake expands “Beyond the Biopsy” National Implementation Forum – November 4, 2026 | Global Liver Institute’s Initiative Expert Panel – November 6, 2026 | Non-Invasive Diagnostics for At-Risk MASH GENFIT’s partner Ipsen is also expected to communicate on elafibranor during The Liver Meeting® 2026. END ABOUT GENFIT GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT focuses on Acute on-Chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow. GENFIT's expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for second-line treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.2 Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. www.genfit.com FORWARD LOOKING STATEMENTS This press release contains certain forward-looking statements with respect to GENFIT, including, but not limited to, statements regarding the development and potential therapeutic profile of nangibotide, the potential role of TREM-1 in Acute-on-Chronic Liver Failure (ACLF), the initiation, design, conduct, timing and results of future clinical trials, including the planned Phase 2a proof-of-concept study in ACLF, the potential clinical benefits, safety profile and therapeutic value of nangibotide, the potential relevance on future clinical investigations of efficacy signals and safety data observed in prior clinical studies conducted in other indications, the expected timing of data readouts, regulatory interactions and future development activities, the potential role, clinical utility and adoption of non-invasive MASH diagnostics, including GENFIT’s NIS™ Technology, in patient identification, disease monitoring and access to care; the potential opportunities associated with increasing uptake of MASH treatments, as well as the Company's strategic plans and objectives. The use of certain words, such as "believe", "potential", "expect", “target”, “may”, “will”, "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties relating to the the Company’s ability to advance its therapeutic programs and initiate and complete clinical trials; uncertainties relating to regulatory requirements and decisions, patient enrollment, clinical trial execution, safety findings, manufacturing and clinical supply; the possibility that findings from prior studies in other indications, preclinical research or ex vivo assays may not predict safety, efficacy or clinical benefit in patients with ACLF; uncertainties relating to the clinical utility, further validation, adoption and use of non-invasive MASH diagnostics, including for disease or treatment- response monitoring; changes in clinical practice, treatment uptake, reimbursement, access and applicable regulatory requirements; and the Company’s dependence on partners and other third parties whose plans and activities may change. Those risks and uncertainties also include those discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2025 Universal Registration Document filed on April 3, 2026 (no. 26-0221) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.fr) and the AMF's website (www.amf.org), and those discussed in reports filed with the AMF or otherwise made public, by the Company including the Half-Year 2026 Business and Financial Report. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACTS GENFIT | Investors Jean-Christophe Marcoux – Chief Corporate Affairs Officer | Tel: +33 3 2016 4000 | Kevin Gardner – Life Science Advisors | [email protected] GENFIT | Media Bruno ARABIAN – Agence Maarc | Tel : 06 87 88 47 26 | [email protected] Stephanie Boyer – Press relations | Tel: +333 2016 4000 | [email protected] GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 1 NIS™ Technology refers to NIS4® and its next-generation version, NIS2+® | NASHnext® (based on NIS4 technology) reimbursement by Medicare under the Clinical Laboratory Fee Schedule to Medicare patients that meet coverage criteria became effective on August 10, 2026 | NIS2+® is currently available through Labcorp in the United States as a Laboratory Developed Test (LDT). It has not been cleared or approved by the U.S. Food,and Drug Administration (FDA) and is not CE marked in the European Union Attachment
|


